FDA Commissioner Dr. Marty Makary tells 'The Hill' on NewsNation what is next for the MAHA movement
FDA Commissioner Dr. Marty Makary joins host Blake Burman to discuss the Trump administration's newly released "Make America Healthy Again" (MAHA) report. Makary asserts that the campaign's goal is to get parents and others to pay attention to some of the environmental factors that their research links to chronic health conditions in the U.S.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing
NEWPORT NEWS, Va., June 9, 2025 /PRNewswire/ -- Dilon Technologies®, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a $9 million growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling. Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes. "We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide," said George Makhoul, CEO of Dilon Technologies. "This funding empowers us to continue delivering best-in-class innovations that improve patient care." HEMOBLAST Bellows® is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST® Bellows continues to redefine standards in surgical hemostasis. Another key product, MarginProbe® an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe® reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end. Dilon's Navigator™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025. "We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide," said Brett Cohen, CEO of JGB Management Inc. For more information, visit About Dilon Technologies® Technologies® Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes: HEMOBLAST Bellows®: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding. MarginProbe®: A groundbreaking real-time margin assessment tool for breast cancer surgery. Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping. TrueView 100 Pro: A surgical specimen analyzer for intraoperative use. CoPilot VL+®: A compact, portable video laryngoscope for airway visualization. About JGB Management Inc. JGB Management Inc., founded by Brett Cohen in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT. View original content to download multimedia: SOURCE Dilon Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
TYBR Health Announces FDA 510(k) Clearance for B3 GEL™ System, a Flowable Bio-Gel to Protect Healing Tissue and Preserve Function
HOUSTON, June 9, 2025 /PRNewswire/ -- TYBR Health, a medical device and regenerative medicine company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the B3 GEL™ System. B3 GEL™ is a bioresorbable, flowable gel barrier designed to protect healing tissue planes and preserve mobility following surgeries involving tendons, ligaments, and skeletal muscle. This clearance marks a significant milestone for TYBR Health, enabling a new approach to support functional recovery in musculoskeletal surgery. B3 GEL™ helps maintain surgical precision by temporarily separating tissues during the early healing phase—without impeding the natural healing process. "When we started TYBR, it was with a clear purpose: to solve a real, overlooked problem in surgical recovery," said Tim Keane, PhD, Cofounder and CEO of TYBR Health. "Too often, healing goes unprotected once the procedure ends. B3 GEL™ is designed to fill that gap—working with the body's biology to protect tissue planes and give surgeons a way to safeguard patient outcomes during the critical early phase of recovery." B3 GEL™ is composed of a naturally derived extracellular matrix and is applied via TYBR's proprietary integrated mixer-applicator system. Its flowable format conforms to complex anatomy and can be used in both open and minimally invasive procedures. The blue-colored gel allows for visual confirmation of placement and resorbs completely over time without leaving residual bulk. Preclinical studies submitted to support clearance demonstrated that B3 GEL™ reduced tissue binding and supported improved range of motion in treated models, with enhanced flexion and extension compared to controls (data on file). TYBR Health plans to begin commercial sales of the B3 GEL™ System by the end of 2025. About TYBR HealthFounded in 2020, TYBR Health is a medical device and regenerative medicine company focused on improving surgical recovery. Headquartered in Houston, Texas, TYBR develops solutions that help surgeons protect healing tissues and preserve function after surgery. Its lead product, the B3 GEL™ System, is a bioresorbable gel barrier cleared by the FDA to aid in the protection of soft tissues during post-surgical healing. TYBR is targeting a significant unmet need in musculoskeletal surgery, where recovery complications impact function and healthcare costs. With FDA clearance secured, manufacturing in place, and a proprietary delivery system developed for precise, intraoperative use, TYBR is preparing for commercial launch in late 2025. For more information contact: info@ View original content to download multimedia: SOURCE TYBR Health
Yahoo
an hour ago
- Yahoo
FDA Announces Recall of Over 20 Million Eggs After Salmonella Outbreak in 7 States
On June 6, 2025, the U.S. Food and Drug Administration (FDA) announced that August Egg Company of Hilmar, California, is recalling over 1,700,000 dozen brown cage-free and brown certified organic eggs, totaling over 20 million eggs. The recall was initiated in response to an ongoing investigation by the FDA and the Centers for Disease Control and Prevention (CDC) into a multistate outbreak of Salmonella that has sickened 79 people and resulted in 21 hospitalizations so far. While the eggs were produced by August Egg Company, they were sold under multiple brand names at restaurants and retailers. This recall includes eggs sold in 6-, 12-, and 18-count packs as well as larger restaurant boxes under the following brand names: Clover, First Street, Nulaid, O Organics, Marketside, Raley's, Simple Truth, Sun Harvest, and Sunnyside. The recalled eggs were distributed from Feb. 3, 2025, through May 6, 2025, to Walmart locations in nine states: Arizona, California, Illinois, Indiana, Nebraska, Nevada, New Mexico, Washington, and Wyoming, These eggs have "sell by" dates ranging from March 4, 2025, to June 4, 2025. The eggs were also distributed from Feb. 3, 2025, through May 15, 2025, to several retailers in California and Nevada, including Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raley's, Food 4 Less, and Ralphs. These eggs have "sell by" dates ranging from March 4, 2025, to June 19, 2025. At this time, the Salmonella outbreak investigation is ongoing, with illnesses reported in seven states: Arizona, California, Kentucky, Nebraska, Nevada, New Jersey, and Washington. The FDA is working to determine if the eggs were distributed to any other retailers in additional states. The recall may be updated as more information becomes available. You can identify the recalled eggs by checking the side of the carton. The recalled eggs feature a printed Julian Date on the side between '32' and '126' followed by a plant code number 'P-6562' or 'CA-5330' on the egg carton or package. The recalled eggs sold to consumers are packed in fiber or plastic cartons, with the above codes printed on one side of the carton. Here is a full list of the recalled eggs, along with their identifying information: Item Name Plant Number Carton UPC Clover Organic Large Brown 12 eggs P-6562 or CA-5330 070852010427 First Street Cage Free Large Brown Loose (1 case = 150 eggs) P-6562 or CA-5330 041512039638 Nulaid Medium Brown Cage Free 12 eggs P-6562 or CA-5330 071230021042 Nulaid Jumbo Brown Cage Free 12 eggs P-6562 or CA-5330 071230021011 O Organics Cage Free Large Brown 6 eggs P-6562 or CA-5330 079893401522 O Organics Large Brown 12 eggs P-6562 or CA-5330 079893401508 O Organics Large Brown 18 eggs P-6562 or CA-5330 079893401546 Marketside Organic Large Cage Free Brown 12 eggs P-6562 or CA-5330 681131122771 Marketside Organic Large Cage Free Brown 18 eggs P-6562 or CA-5330 681131122801 Marketside Large Cage Free Brown 12 eggs P-6562 or CA-5330 681131122764 Marketside Large Cage Free Brown 18 eggs P-6562 or CA-5330 681131122795 Raley's Large Cage Free Brown 12 eggs P-6562 or CA-5330 046567033310 Raley's Large Cage Free Brown 18 eggs P-6562 or CA-5330 046567040325 Raley's Organic Large Cage Free Brown 12 eggs P-6562 or CA-5330 046567028798 Raley's Organic Large Cage Free Brown 18 eggs P-6562 or CA-5330 046567040295 Simple Truth Medium Brown Cage Free 18 eggs P-6562 or CA-5330 011110099327 Simple Truth Large Brown Cage Free 18 eggs P-6562 or CA-5330 011110873743 Sun Harvest Organic Cage Free Large Brown 12 eggs P-6562 or CA-5330 041512131950 Sun Harvest Organic Cage Free Large Brown 18 eggs P-6562 or CA-5330 041512145162 Sunnyside Large Brown Cage Free 12 eggs P-6562 or CA-5330 717544211747 Sunnyside Large Brown Cage Free 18 eggs P-6562 or CA-5330 717544211754 Sunnyside Organic Cage Free Large Brown 12 eggs P-6562 or CA-5330 717544201441 Sunnyside Organic Cage Free Large Brown 18 eggs P-6562 or CA-5330 717544211761 Loose Small Brown Cage Free (1 box = 6 flats) (1 flat = 30 eggs) P-6562 or CA-5330 NA Loose Medium Brown Cage Free (1 box = 6 flats) (1 flat = 30 eggs) P-6562 or CA-5330 NA Loose Medium Brown Organic (1 box = 6 flats) (1 flat = 30 eggs) P-6562 or CA-5330 NA Loose Large Brown Organic (1 box = 6 flats) (1 flat = 30 eggs) P-6562 or CA-5330 NA Loose Jumbo Brown Cage Free (1 box = 5 flats) (1 flat = 20 eggs) P-6562 or CA-5330 NA Loose Jumbo Brown Organic (1 box = 5 flats) (1 flat = 20 eggs) P-6562 or CA-5330 NA You can also view photos of the labels on the FDA website. The recalled eggs are no longer in stores, but the FDA is concerned they may still be in consumers' homes. Per FDA guidance, check your refrigerators for the recalled brown cage-free and brown certified organic eggs. If you have the recalled eggs, throw them away or return them to the original place of purchase for a full refund. If you stored the eggs without their original packaging and can't tell if they are part of this outbreak, the FDA urges you to discard them out of an abundance of caution. Additionally, be sure to carefully clean and sanitize any surfaces that may have come in contact with the contaminated eggs. Further questions about this recall may be directed to August Egg Company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT. If you believe you have already consumed the recalled eggs, you should monitor yourself for symptoms of a Salmonella infection. The most common symptoms include diarrhea, stomach cramps, dehydration, vomiting, and fever higher than 102°F—and, typically, symptoms begin between six hours and six days after eating the contaminated food. If you're experiencing any of those symptoms, contact your healthcare provider. While most individuals feel better after four to seven days, Salmonella can cause serious infections in children, older individuals, and those with weakened immune systems. To learn more about Salmonella, visit the CDC website. Read the original article on ALLRECIPES
